Hector M González1, Wassim Tarraf2, Kevin A González1, Myriam Fornage3, Donglin Zeng4, Linda C Gallo5, Gregory A Talavera5, Martha L Daviglus6, Richard B Lipton7, Robert Kaplan7,8, Alberto R Ramos9, Melissa Lamar6,10, Jianwen Cai4, Charles DeCarli11, Neil Schneiderman12. 1. Department of Neurosciences and Shiley-Marcos Alzheimer's Disease Research Center, University of California, San Diego, San Diego, CA hmg002@health.ucsd.edu. 2. Institute of Gerontology and Department of Healthcare Sciences, Wayne State University, Detroit, MI. 3. University of Texas Health Science Center, Houston, TX. 4. Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC. 5. Department of Psychology, San Diego State University, San Diego, CA. 6. Institute for Minority Health Research, College of Medicine, University of Illinois at Chicago, Chicago, IL. 7. Albert Einstein College of Medicine, New York, NY. 8. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA. 9. Department of Neurology, University of Miami, Miami, FL. 10. Department of Psychiatry and Behavioral Sciences and Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL. 11. Department of Neurology and Alzheimer's Disease Center, University of California, Davis, Sacramento, CA. 12. Department of Psychology, University of Miami, Miami, FL.
Abstract
OBJECTIVE: Hispanics/Latinos are the largest ethnic/racial group in the U.S., have the highest prevalence of diabetes, and are at increased risk for neurodegenerative disorders. Currently, little is known about the relationship between diabetes and cognitive decline and disorders among diverse Hispanics/Latinos. The purpose of this study is to clarify these relationships in diverse middle-aged and older Hispanics/Latinos. RESEARCH DESIGN AND METHODS: The Study of Latinos-Investigation of Neurocognitive Aging (SOL-INCA) is an ancillary study of the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). HCHS/SOL is a multisite (Bronx, NY; Chicago, IL; Miami, FL; and San Diego, CA), probability-sampled (i.e., representative of targeted populations), and prospective cohort study. Between 2016 and 2018, SOL-INCA enrolled diverse Hispanics/Latinos aged ≥50 years (n = 6,377). Global cognitive decline and mild cognitive impairment (MCI) were the primary outcomes. RESULTS: Prevalent diabetes at visit 1, but not incident diabetes at visit 2, was associated with significantly steeper global cognitive decline (βGC = -0.16 [95% CI -0.25; -0.07]; P < 0.001), domain-specific cognitive decline, and higher odds of MCI (odds ratio 1.74 [95% CI 1.34; 2.26]; P < 0.001) compared with no diabetes in age- and sex-adjusted models. CONCLUSIONS: Diabetes was associated with cognitive decline and increased MCI prevalence among diverse Hispanics/Latinos, primarily among those with prevalent diabetes at visit 1. Our findings suggest that significant cognitive decline and MCI may be considered additional disease complications of diabetes among diverse middle-aged and older Hispanics/Latinos.
OBJECTIVE: Hispanics/Latinos are the largest ethnic/racial group in the U.S., have the highest prevalence of diabetes, and are at increased risk for neurodegenerative disorders. Currently, little is known about the relationship between diabetes and cognitive decline and disorders among diverse Hispanics/Latinos. The purpose of this study is to clarify these relationships in diverse middle-aged and older Hispanics/Latinos. RESEARCH DESIGN AND METHODS: The Study of Latinos-Investigation of Neurocognitive Aging (SOL-INCA) is an ancillary study of the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). HCHS/SOL is a multisite (Bronx, NY; Chicago, IL; Miami, FL; and San Diego, CA), probability-sampled (i.e., representative of targeted populations), and prospective cohort study. Between 2016 and 2018, SOL-INCA enrolled diverse Hispanics/Latinos aged ≥50 years (n = 6,377). Global cognitive decline and mild cognitive impairment (MCI) were the primary outcomes. RESULTS: Prevalent diabetes at visit 1, but not incident diabetes at visit 2, was associated with significantly steeper global cognitive decline (βGC = -0.16 [95% CI -0.25; -0.07]; P < 0.001), domain-specific cognitive decline, and higher odds of MCI (odds ratio 1.74 [95% CI 1.34; 2.26]; P < 0.001) compared with no diabetes in age- and sex-adjusted models. CONCLUSIONS:Diabetes was associated with cognitive decline and increased MCI prevalence among diverse Hispanics/Latinos, primarily among those with prevalent diabetes at visit 1. Our findings suggest that significant cognitive decline and MCI may be considered additional disease complications of diabetes among diverse middle-aged and older Hispanics/Latinos.
Authors: Sylvia Wassertheil-Smoller; Elva M Arredondo; JianWen Cai; Sheila F Castaneda; James P Choca; Linda C Gallo; Molly Jung; Lisa M LaVange; Elizabeth T Lee-Rey; Thomas Mosley; Frank J Penedo; Daniel A Santistaban; Phyllis C Zee Journal: Ann Epidemiol Date: 2014-09-11 Impact factor: 3.797
Authors: Paul D Sorlie; Larissa M Avilés-Santa; Sylvia Wassertheil-Smoller; Robert C Kaplan; Martha L Daviglus; Aida L Giachello; Neil Schneiderman; Leopoldo Raij; Gregory Talavera; Matthew Allison; Lisa Lavange; Lloyd E Chambless; Gerardo Heiss Journal: Ann Epidemiol Date: 2010-08 Impact factor: 3.797
Authors: Lisa M Lavange; William D Kalsbeek; Paul D Sorlie; Larissa M Avilés-Santa; Robert C Kaplan; Janice Barnhart; Kiang Liu; Aida Giachello; David J Lee; John Ryan; Michael H Criqui; John P Elder Journal: Ann Epidemiol Date: 2010-08 Impact factor: 3.797
Authors: E van den Berg; Y D Reijmer; J de Bresser; R P C Kessels; L J Kappelle; G J Biessels Journal: Diabetologia Date: 2009-10-31 Impact factor: 10.122
Authors: L Jaime Fitten; Freddy Ortiz; Lynn Fairbanks; George Bartzokis; Po Lu; Eric Klein; Giovanni Coppola; John Ringman Journal: Int J Geriatr Psychiatry Date: 2014-01-29 Impact factor: 3.485
Authors: Rosebud O Roberts; David S Knopman; Yonas E Geda; Ruth H Cha; V Shane Pankratz; Luke Baertlein; Bradley F Boeve; Eric G Tangalos; Robert J Ivnik; Michelle M Mielke; Ronald C Petersen Journal: Alzheimers Dement Date: 2013-04-03 Impact factor: 21.566
Authors: Hector M González; Wassim Tarraf; Myriam Fornage; Kevin A González; Albert Chai; Marston Youngblood; Maria de Los Angeles Abreu; Donglin Zeng; Sonia Thomas; Gregory A Talavera; Linda C Gallo; Robert Kaplan; Martha L Daviglus; Neil Schneiderman Journal: Alzheimers Dement Date: 2019-11-20 Impact factor: 21.566
Authors: Neil Schneiderman; Maria Llabre; Catherine C Cowie; Janice Barnhart; Mercedes Carnethon; Linda C Gallo; Aida L Giachello; Gerardo Heiss; Robert C Kaplan; Lisa M LaVange; Yanping Teng; Leonel Villa-Caballero; M Larissa Avilés-Santa Journal: Diabetes Care Date: 2014-08 Impact factor: 19.112
Authors: Bayan Moustafa; Gabriela Trifan; Carmen R Isasi; Richard B Lipton; Daniela Sotres-Alvarez; Jianwen Cai; Wassim Tarraf; Ariana Stickel; Josiemer Mattei; Gregory A Talavera; Martha L Daviglus; Hector M González; Fernando D Testai Journal: JAMA Netw Open Date: 2022-07-01
Authors: Zvinka Z Zlatar; Wassim Tarraf; Kevin A González; Priscilla M Vásquez; María J Marquine; Richard B Lipton; Linda C Gallo; Tasneem Khambaty; Donglin Zeng; Marston E Youngblood; Mayra L Estrella; Carmen R Isasi; Martha Daviglus; Hector M González Journal: Alzheimers Dement Date: 2021-05-31 Impact factor: 16.655
Authors: Jordana Breton; Ariana M Stickel; Wassim Tarraf; Kevin A Gonzalez; Alexandra J Keamy; Neil Schneiderman; María J Marquine; Zvinka Z Zlatar; David P Salmon; Melissa Lamar; Martha L Daviglus; Richard B Lipton; Linda C Gallo; Zachary T Goodman; Hector M González Journal: Alzheimers Dement (Amst) Date: 2021-12-07